Quarterly Result28 May 2025, 01:54 pm
Granules India Reports Q4FY25 Revenue Growth of 2%, EBITDA Down 1%, PAT Up 17% YoY
AI Summary
Granules India Ltd., a vertically integrated pharmaceutical company, announced its financial results for the quarter and financial year ended March 31, 2025. The company reported a 2% YoY growth in revenue from operations, a 1% YoY decrease in EBITDA, and a 17% YoY increase in PAT. The revenue share from North America increased to 79% in Q4 FY25 as compared to 70% in Q4 FY24. The company's product mix focus on high-margin offerings and expanding portfolio of non-legacy molecules contributed to the strong financial performance.
Key Highlights
- Revenue from Operations for Q4FY25 stood at INR 11,974 mn, a growth of 2% YoY
- EBITDA for Q4FY25 was INR 2,524 mn, down 1% YoY
- PAT for Q4FY25 was INR 1,520 mn, up 17% YoY
- Revenue share from North America increased to 79% in Q4 FY25
- Company's strategic initiatives, particularly focus on enhancing product mix, contributed to the strong financial performance